Tirze
Dual GIP/GLP-1 receptor agonist. FDA-approved for type 2 diabetes (GLP2TZ) and obesity (GLP2TZ). The most-studied modern metabolic peptide with robust Phase III clinical data for weight management.
Tirze is a synthetic dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (GCG-like peptide-1) receptor agonist developed by Eli Lilly. It is FDA-approved under the brand name GLP2TZ for type 2 diabetes management and under GLP2TZ for chronic weight management in adults with obesity or overweight with a weight-related condition.
The dual incretin mechanism — activating both GIP and GLP-1 receptors — produces greater metabolic effects than single GLP-1 agonism alone. The GIP component is believed to enhance insulin secretion, reduce GCG, improve insulin sensitivity, and may contribute to the improved GI tolerability profile observed versus single GLP-1 agonists in some studies.
The SURMOUNT clinical trial program demonstrated up to 22.5% mean body weight loss in participants with obesity — outcomes that have substantially shifted the treatment landscape for chronic weight management. Tirze represents the most clinically validated metabolic peptide currently available.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
Tirze has an established safety profile from Phase III trials. Most common adverse effects are GI-related: nausea, diarrhea, vomiting, and constipation — typically worst during titration and diminishing over time. Risk of thyroid C-cell tumors seen in rodents; contraindicated in patients with personal/family history of medullary thyroid carcinoma.
Research vial use for self-administration outside physician supervision carries significant risks. Sub-label microdosing protocols are off-label with no established safety or efficacy data.